# Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

> **NCT01104155** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 123 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** eribulin mesylate + erlotinib
- **DRUG:** eribulin mesylate + erlotinib

## Key facts

- **NCT ID:** NCT01104155
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-22
- **Primary completion:** 2011-04-07
- **Final completion:** 2017-01-18
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01104155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01104155, "Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01104155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*